glp 1 drugs and fatty liver Therapeutic Mechanisms Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Disease The GLP-1 Era: Why These

So while these medications are very effective and have been studied in long trials, there is a substantial portion who won't achieve at least 5% weight loss

The connection remains investigational, and any effects on alcohol consumption should be considered preliminary findings requiring rigorous clinical validation

The researchers compared both doses against a placebo

In one, patients who lost 10.6% of their weight after 20 weeks of Wegovy were randomized to continue it or switch to placebo

Meanwhile, Wegovy is facing tough competition from Eli Lilly's weight-loss therapy Zepbound (tirzepatide), which outperformed its rival in the head-to-head SURMOUNT-5 trial